Case Study: Early Alliances and Risk Sharing Portfolios: An Academic’s Perspective

Dr. Catherine Tralau, Head of Drug Discovery Facility & Pharmacology Imperial College London, discusses the growth of robust drug discovery models within academia and why the academic virtual biotech model within Imperial is such an efficient option. Tralau also shares her insights on the importance of early phase collaborations to deliver Pharma’s future pipeline and challenging the traditional Pharma drug discovery model.

Presented at Pharma IQ's Global Discovery Outsourcing and Collaborations Forum in October 2010.

To continue reading this story get free access